EYE 주식 개요 Nova Eye Medical Limited는 호주, 미국, 유럽, 아시아 태평양 및 국제적으로 녹내장 치료를 위한 수술 기기를 설계, 개발, 제조, 마케팅 및 판매하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Nova Eye Medical Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Nova Eye Medical 과거 주가 현재 주가 AU$0.14 52주 최고치 AU$0.33 52주 최저치 AU$0.12 베타 0.92 1개월 변경 -9.38% 3개월 변경 사항 -14.71% 1년 변경 사항 20.83% 3년 변화 -53.23% 5년 변화 -80.27% IPO 이후 변화 -75.54%
최근 뉴스 및 업데이트 더 많은 업데이트 보기
We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth Nov 04
Nova Eye Medical Limited, Annual General Meeting, Nov 21, 2024 Sep 27
Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26% Sep 22
Consensus EPS estimates fall by 26% Sep 03
Price target increased by 18% to AU$0.59 Sep 02
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 27
Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE) Aug 06
New minor risk - Share price stability Aug 06
New minor risk - Profitability May 09
Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward Apr 18
Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation? Mar 26
Forecast breakeven date pushed back to 2026 Mar 26
Consensus revenue estimates decrease by 14% Mar 23 Nova Eye Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 8.435798 million. Mar 15
Nova Eye Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 8.004324 million. Feb 13 Nova Eye Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 8.004324 million. Feb 12
News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts Jan 19
Consensus revenue estimates increase by 23% Jan 12
Forecast breakeven date pushed back to 2026 Dec 31
Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce Dec 27
New minor risk - Share price stability Oct 28
Nova Eye Medical Limited, Annual General Meeting, Nov 23, 2023 Sep 26
We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate Sep 03
Full year 2023 earnings: EPS and revenues miss analyst expectations Aug 30
New major risk - Revenue and earnings growth Aug 30
Nova Eye Medical Limited to Report Fiscal Year 2023 Results on Aug 28, 2023 Aug 24
Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified Apr 17
First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.021 loss in 1H 2022) Mar 03
Nova Eye Medical Limited to Report First Half, 2023 Results on Feb 27, 2023 Jan 30
Nova Eye Medical Limited Announces New, Additional Clinical Application for 2RT Currently Under Investigation Jan 25
Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth? Dec 16
Nova Eye Medical Limited Receives Feedback from the US Food & Drug Administration in Relation to Its 510(K) Submission for Marketing Clearance of the Company's New iTrack Advance Canaloplasty Device in the USA Dec 13
Nova Eye Medical Limited Appoints Daniel (Dan) Webb as Director Nov 18
Price target increased to AU$0.90 Nov 16
Less than half of directors are independent Nov 16
Nova Eye Medical Limited Completes Initial Recruitment of Investigator Sites Oct 24 Nova Eye Medical Limited, Annual General Meeting, Nov 17, 2022 Sep 15
We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully Aug 27
Full year 2022 earnings: EPS and revenues miss analyst expectations Aug 26
Nova Eye Medical Limited Announces the Commencement of the Commercial Roll-Out of its Next Generation Canaloplasty Device, iTrack Advance, in Select Markets in Europe and the Asia Pacific Jun 10
Price target decreased to AU$0.70 Apr 27
Less than half of directors are independent Apr 27
Nova Eye Medical Limited to Report First Half, 2022 Results on Feb 14, 2022 Feb 01
Less than half of directors are independent Dec 23
Non-Executive Director Alexander Sundich has left the company Nov 29
Non-Executive Director Alexander Sundich has left the company Nov 29
Non-Executive Director Alexander Sundich has left the company Nov 29
Non-Executive Director Alexander Sundich has left the company Nov 29
Non-Executive Director Alexander Sundich has left the company Nov 29
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 28
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 27
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26
Non-Executive Director Alexander Sundich has left the company Nov 26 주주 수익률 EYE AU Medical Equipment AU 마켓 7D 3.6% -1.1% -2.7% 1Y 20.8% 0.4% 6.5%
전체 주주 수익률 보기
수익률 대 산업: EYE 지난 1년 동안 0.4 %를 반환한 Australian Medical Equipment 산업을 초과했습니다.
수익률 대 시장: EYE 지난 1년 동안 6.5 %를 반환한 Australian 시장을 초과했습니다.
가격 변동성 Is EYE's price volatile compared to industry and market? EYE volatility EYE Average Weekly Movement 8.1% Medical Equipment Industry Average Movement 8.8% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
안정적인 주가: EYE 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: EYE 의 주간 변동성 ( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 Nova Eye Medical Limited는 호주, 미국, 유럽, 아시아 태평양 및 전 세계에서 녹내장 치료를 위한 수술 기기를 설계, 개발, 제조, 마케팅 및 판매합니다. 이 회사는 개방각 녹내장 성인 환자의 안압을 낮추는 녹내장 수술 기기인 iTrack, 일반적인 나일론 대체품보다 가단성과 기동성을 제공하는 운하 성형 미세 카테터인 iTrack Advance, 중증 또는 복합 녹내장 환자를 치료하는 녹내장 배액 장치인 Molteno3, 초기/중기 연령 관련 황반변성 환자 치료를 위한 독점 레이저 기술인 2RT를 제공합니다. 이 회사는 이전에는 Ellex Medical Lasers Limited로 알려졌으나 2020년 7월에 Nova Eye Medical Limited로 사명을 변경했습니다.
자세히 보기 Nova Eye Medical Limited 기본 사항 요약 Nova Eye Medical 의 수익과 매출은 시가총액과 어떻게 비교하나요? EYE 기본 통계 시가총액 AU$33.21m 수익(TTM ) -AU$8.79m 수익(TTM ) AU$23.33m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) EYE 손익 계산서(TTM ) 수익 AU$23.33m 수익 비용 AU$3.13m 총 이익 AU$20.19m 기타 비용 AU$28.98m 수익 -AU$8.79m
주당 순이익(EPS) -0.038 총 마진 86.57% 순이익 마진 -37.68% 부채/자본 비율 0%
EYE 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/20 16:23 장 마감 주가 2024/12/20 00:00 수익 2024/06/30 연간 수익 2024/06/30
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Nova Eye Medical Limited 4 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Tanushree Jain Bell Potter Anthony Vendetti Maxim Group Michael Youlden MST Financial Services Pty Limited
1 더 많은 분석가 보기 
